The effectiveness of COVID-19 vaccination

Organizer:
Institute for Interdisciplinary Health Research (IIHR)
Project start date:
2021-06-21
Project end date:
2022-10-10

The European University at St. Petersburg, Medical Institute named after Berezin Sergey and Tarusa hospital conducted two observational studies to assess the effectiveness of vaccination against symptomatic infection caused by the Delta variant in St. Petersburg.

Project News

Sputnik V protects against lung damage caused by the Delta and Omicron strains

18.07.2022
Researchers from the European University and the Sergey Berezin Medical Institute (MIBS) have calculated the effectiveness of Russian vaccines against lung damage during COVID-19 waves caused by  the Delta and Omicron strains. The effectiveness of two doses of Sputnik V was 56%. The effectiveness of three doses was 71%.  EpiVacCorona was not shown to be effective. 

"Sputnik V" protects against the delta variant of SARS-CoV-2: results of an independent study

25.01.2022
Researchers from the European University at St. Petersburg and the Medical Institute named after Berezin Sergey (MIBS) calculated the effectiveness of Russian vaccines against symptomatic coronavirus infection during an outbreak caused by the delta variant. "Sputnik V" protects against the delta variant. Тhe effectiveness of the vaccine was 58%. In reality, the efficacy is even higher, since this calculated figure is influenced by the number of people who recovered but were not included in the data.

The material based on the results of the preprint on the study of the effectiveness of vaccination is published in Science

27.08.2021
The journal Science of the American Association for the Advancement of Science published an article about an independent study of the effectiveness of vaccination, which was conducted by scientists from the European University, the Medical Institute named after Sergey Berezin, the First honey in St. Petersburg and the Tarus Hospital.

Публикации проекта

Gam-COVID-Vac, EpiVacCorona, and CoviVac effectiveness against lung injury during Delta and Omicron variant surges in St. Petersburg, Russia: a test-negative case–control study

Author(s):

Anton Barchuk, Anna Bulina, Mikhail Cherkashin, Natalia Berezina, Tatyana Rakova, Darya Kuplevatskaya, Dmitriy Skougarevskiy, Artemiy Okhotin

Year of publication:

Monitoring vaccine effectiveness (VE) remains a priority for epidemiological research throughout the COVID-19 pandemic. VE against infection declines with the emergence of new SARS-CoV-2 variants of concern (VOC), but VE against the severe disease remains high. Therefore, we aimed to estimate the effectiveness of COVID-19 vaccines used in Russia against lung injury during Delta and Omicron VOC surges.

COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 during Delta variant surge: a preliminary assessment from a case-control study in St. Petersburg, Russia

Author(s):

Anton Barchuk, Anna Bulina, Mikhail Cherkashin, Natalia Berezina, Tatyana Rakova, Darya Kuplevatskaya, Oksana Stanevich, Dmitriy Skougarevskiy, Artemiy Okhotin

Тип издания:
Журнал
Year of publication:

No studies estimated vaccine effectiveness of Gam-COVID-Vac and other vaccines used in Russia against symptomatic infection with Delta variant. In this population-based case-control study, the authors aimed to estimate the effectiveness of the Russian COVID-19 vaccines against symptomatic SARS-CoV-2 during the recent outbreak caused by the Delta VOC in October 2021 in St. Petersburg, Russia.

Vaccine effectiveness against referral to hospital after SARS-CoV-2 infection in St. Petersburg, Russia, during the Delta variant surge: a test-negative case-control study

Author(s):

Anton Barchuk, Mikhail Cherkashin, Anna Bulina, Natalia Berezina, Tatyana Rakova, Darya Kuplevatskaya, Oksana Stanevich, Dmitriy Skougarevskiy, Artemiy Okhotin

Тип издания:
Журнал
Year of publication:

The results of a randomised trial showed the safety and efficacy of Gam-COVID-Vac against COVID-19. However, compared to other vaccines used across the globe, the real-world data on the effectiveness of Gam-COVID-Vac, especially against the disease caused by the Delta variant of concern, was limited. The authors aimed to assess the effectiveness of vaccination mainly conducted with Gam-COVID-Vac in St. Petersburg, Russia. They estimated the  vaccine effectiveness against referral for hospital admission, COVID-19-related lung injury assessed with LDCT, and decline in oxygen saturation.